Table 1. Drugs and approval endpoints (33), OS=overall survival, ORR=objective response rate, TTP=time to progression, NSCLC=non-small-cell lung cancer.
| Drugs / Regimens and Approval endpoints | |
|---|---|
| First-line NSCLC | |
| Vinorelbine monotherapy | OS, ORR |
| Vinorelbine + cisplatin | OS, ORR |
| Docetaxel + cisplatin | OS, TTP, ORR |
| Gemcitabine + cisplatin | OS, TTP, ORR |
| Bevacizumab† + paclitaxel/carboplatin | OS |
| Paclitaxel + cisplatin | TTP, ORR, OS |
| Pemetrexed in combination with cisplatin†,‡ | OS |
| Pemetrexed as maintenance therapy† | OS |
| Second-line NSCLC | |
| Docetaxel | OS, TTP, ORR |
| Erlotinib | OS, TTP. ORR |
| Pemetrexed†,‡ | Durable ORR, decreased toxicity |
| Third-line NSCLC | |
| Erlotinib | OS, TTP, ORR |
| Gefitinib‡ | Durable ORR |
†Limited to non-squamous non-small cell lung cancer; ‡Accelerated approval.